Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 11/20 | 0.38 |
| ▸ | CA1 | P00915 | 9/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127202 | 0.92 | HDAC1 (0.36) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7127418 | 0.91 | IDO1 (0.39) | IDO1CA2CA1NQO2CA12 | |
| SCHEMBL7126887 | 0.83 | DRD2 (0.36) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7127208 | 0.82 | HDAC1 (0.36) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7131539 | 0.81 | CA1 (0.44) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7166193 | 0.81 | CA1 (0.45) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7134803 | 0.80 | CA1 (0.37) | IDO1CA2CA1NQO2CA12 | |
| SCHEMBL7249512 | 0.80 | SIGMAR1 (0.37) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7132936 | 0.78 | CA12 (0.41) | IDO1CA2CA1CA12CA9 | |
| SCHEMBL7132941 | 0.78 | CA12 (0.41) | IDO1CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | IDO1 4214/4885CA2 3155/4885CA1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.